30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

Company Revenue 2015: Biomet

For period ended 2/28/15, 3QFY15

$740.1MM, -2%

  • Hips $160.2MM, +4%
  • Knees $247.3MM, +1%
  • Sports Med/Extremities/Trauma $163.2MM, flat
  • Spine, Bone Healing & Microfixation $117.3MM, +3%
  • Cement, Biologics & Other $52.1MM, -0.4%


  • Strong global acceptance of G7 multibearing acetabular system, demand for Taperloc Complete and Microplasty systems, Arcos modular femoral revision system
  • Strong sales of XPA bicruciate preserving solutions: Oxford Partial, Vanguard XP Total knee
  • Anatomic & reverse shoulder contributed to sales growth
  • Signature patient-specific guides still well-received
  • Juggerknotless All-suture continues to be strongly accepted
  • 1st fully comparable quarter of sales since acquisition of Lanx